Poor
Not Aligned
Patient Risk:
High
Summary
Partially aligns on skeletal muscle adverse effects and some risk-factor and drug-interaction statements, but includes multiple unsupported epidemiologic/statistical claims and several risk-factor/management assertions not supported by the provided FDA label text; also omits other critical label elements (e.g., contraindications/pregnancy/lactation) relevant to safe labeling-adjacent content.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is used to prevent cardiovascular disease.
1.1 Prevention of Cardiovascular Disease
Lipitor (atorvastatin) is associated with muscle-related adverse effects.
5.1 Skeletal Muscle; 6 ADVERSE REACTIONS
Muscle-related side effects with Lipitor (atorvastatin) include myopathies.
5.1 Skeletal Muscle
Muscle-related side effects with Lipitor (atorvastatin) can include rhabdomyolysis.
5.1 Skeletal Muscle; 6 ADVERSE REACTIONS
Older adults are a risk factor for developing muscle-related side effects with Lipitor (atorvastatin).
8.5 Geriatric Use; 5.1 Skeletal Muscle
Impaired kidney function is a risk factor for developing muscle-related side effects with Lipitor (atorvastatin).
5.1 Skeletal Muscle (history of renal impairment may be a risk factor)
Cyclosporine can increase the risk of muscle-related side effects when taken with Lipitor (atorvastatin).
7 DRUG INTERACTIONS; 5.1 Skeletal Muscle
If muscle-related side effects occur with Lipitor (atorvastatin), a healthcare provider may recommend discontinuing Lipitor (atorvastatin).
5.1 Skeletal Muscle (LIPITOR therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected)
Unsupported Statements
Lipitor (atorvastatin) is a prescription medication used to lower cholesterol levels.
Not supported by the provided label sections (label text supplied does not explicitly state this wording).
Rhabdomyolysis is a potentially life-threatening condition characterized by muscle damage and release of muscle enzymes into the bloodstream.
The provided label text mentions rare cases with acute renal failure, but does not include the described characterization (life-threatening, muscle enzymes into bloodstream) in the supplied sections.
According to the FDA, muscle-related side effects are one of the most common adverse effects associated with Lipitor (atorvastatin).
No provided label text states 'one of the most common adverse effects' for muscle-related effects.
Approximately 1.5% of patients taking Lipitor (atorvastatin) experienced muscle-related side effects... in a study published in the Journal of Clinical Pharmacology.
No such incidence/statistic or citation is present in the provided label sections.
Liver disease or impaired liver function is a risk factor for developing muscle-related side effects with Lipitor (atorvastatin).
The provided label text links liver dysfunction to liver enzyme abnormalities/warnings, but the specific claim as a muscle-risk factor is not supported in the supplied skeletal muscle section.
Pre-existing muscle disorders, such as myasthenia gravis, are a risk factor for developing muscle-related side effects with Lipitor (atorvastatin).
No support in the provided skeletal muscle or interaction text for myasthenia gravis as a risk factor.
Gemfibrozil can increase the risk of muscle-related side effects when taken with Lipitor (atorvastatin).
The provided drug interaction section states fibric acid derivatives increase risk, but 'gemfibrozil' is not explicitly supported in the provided excerpts.
Symptoms of muscle-related side effects with Lipitor (atorvastatin) may include moderate muscle pain and weakness.
The label describes muscle aches/weakness (myopathy) and CPK thresholds, but does not define 'moderate' severity.
Discontinuing Lipitor (atorvastatin) is recommended to allow the muscle-related side effects to resolve, according to the provided text.
The label supports discontinuation when myopathy/markedly elevated CPK occur, but does not state that discontinuation is recommended specifically to 'allow...to resolve' in the supplied text.
If muscle-related side effects occur with Lipitor (atorvastatin), a healthcare provider may recommend switching to alternative medications to manage cholesterol levels.
The provided label excerpts do not mention switching to alternative cholesterol medications in this context.
Regular monitoring of muscle enzymes and kidney function is recommended to prevent further muscle damage in the context of muscle-related side effects with Lipitor (atorvastatin).
The label mentions periodic CPK determinations may be considered and closer monitoring in renal impairment, but does not explicitly recommend monitoring 'kidney function' to prevent further muscle damage in the provided text.
Taking Lipitor (atorvastatin) exactly as prescribed and not exceeding the recommended dose can reduce the risk of muscle-related side effects, according to the provided text.
The label supports risk increase with higher doses and provides specific interacting-agent dosing limits, but does not explicitly state this general phrasing ('exactly as prescribed' as a risk reducer).
Regularly monitoring muscle function and reporting changes to a healthcare provider can reduce the risk of muscle-related side effects with Lipitor (atorvastatin), according to the provided text.
The label advises prompt reporting and considers CPK in certain situations, but does not explicitly state that these actions 'can reduce the risk'.
Avoiding interactions... by informing a healthcare provider of all medications being taken can reduce the risk of muscle-related side effects... according to the provided text.
The label supports discussing medications and risk increase with interacting drugs, but does not explicitly state that informing providers 'can reduce the risk'.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Pregnancy/lactation risk statements and pregnancy-related contraindication/counseling (critical labeling safety content not addressed by any provided claims).
Importance:
High
Contraindications beyond skeletal muscle concerns (provided label includes active liver disease as a contraindication; not addressed).
Importance:
High
Explicit discontinuation guidance wording tied to label criteria for CPK/myopathy (some management claims are present but lack label-precise rationale).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Unsupported epidemiologic/statistical claims and unsupported/overstated risk-factor and management statements could mislead labeling-adjacent patient education; omission of critical contraindication/pregnancy information increases safety risk.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple unsupported claims (incidence/statistics, risk-factor specifics, interaction agent specificity, and risk-reduction wording) plus missing critical label elements (contraindications and pregnancy/lactation counseling).
Suggested Improvement
Remove unsupported prevalence/statistics and external-source attributions; align risk-factor and interaction statements with explicit label wording (e.g., fibric acid derivatives without asserting gemfibrozil unless explicitly stated); use label-precise management language (CPK/myopathy criteria) without claiming resolution/switching/quantified monitoring benefits unless present; add missing critical sections such as contraindications and pregnancy/lactation risk counseling.